Gene Therapy

The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

Insights from a genome-wide association study identify novel genetic loci

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

A large-scale study indicates women are more likely to develop the inherited corneal condition

ENCELTO is the first and only FDA-approved treatment for MacTel.

Neurologist warns about recurrent optic neuritis attacks.

ENCELTO is the first and only FDA-approved treatment for MacTel.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

Emerging technologies, such as remote tonometry and genetic risk scoring, are revolutionizing glaucoma care by enabling earlier detection, personalized management, and more efficient use of resources.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.